LymphedemaLymphedema of FaceInternal LymphedemaExternal LymphedemaLymphedema of Neck
Investigational drug(s) / intervention(s)
Symani Surgical System
Symani Surgical System: Symani® Surgical System is intended to perform surgical techniques during open microsurgical procedures.
Study summary
The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during open lymphatic reconstruction in the head and neck.
Eligibility
Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. At least 22 years of age
2. Patients with acquired head and neck lymphedema with external lymphedema or both external and internal lymphedema
3. Patient agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic-assisted procedure
4. Patient has a clinical indication for a microsurgical anastomosis of vessels between 0.1 and 2.5 mm in conjunction with lymphatic reconstruction of the head and neck
5. Patient has been compliant with complete decongestive therapy (CDT) for at least 4 weeks
6. Patient has undergone lymphatic mapping of the head and neck and functional lymphatic structures for reconstruction have been identified
7. Investigator deems the candidate acceptable for lymphatic reconstruction with a robotic-assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)
8. Willingness to comply with recommended regimen of self-care, with consistent use of manual lymph drainage and/or appropriately sized compression garments from screening through the entire study duration (through the 6-month follow-up visit).
Exclusion Criteria:
1. Patient who is incapable and/or unwilling to provide informed consent
2. Patients with irreversible head and neck lymphedema, defined as stage 3 of the MD Anderson Cancer Center Head and Neck Lymphedema Rating Scale
3. Active systemic infection under treatment with intravenous antibiotics
4. Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigator's discretion
5. Known history of significant bleeding, coagulopathy, or Von Willebrand's disease
6. Currently receiving chemotherapy or radiation therapy (uncontrolled tumor)
7. A history of malignancy or cancer treatment within the past 6 months (tumor control)
8. Patient with unsatisfactory manual lymphatic drainage and/or compression garments for at least six months
9. Patient with prior lymphatic reconstruction in the targeted head \& neck area
10. Patient's lymphatic disease is due to lipedema
11. Patients with other medical conditions that could result in symptoms which overlap symptoms of lymphedema (e.g., thrombosis in the external or internal jugular vein)
12. Current infection in the head \& neck area in which lymphedema is present
13. Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or outcomes
14. Patient is ineligible to participate for other reasons in the judgement of the investigator
Primary outcome measure(s)
Intraoperative anastomosis patency prior to closure. — The duration of the participants' index procedure. Intraoperative anastomosis patency prior to closure will be measured for each robotic anastomosis using indocyanine green (ICG) fluorescence imaging and will be evaluated prior to closure of the procedure site during the index procedure.
Freedom from device-related adverse events — The duration of the participants' index procedure through 30 days. All adverse events will be evaluated from the start of the index procedure through 30 days post index procedure.
Trial sites (1)
Facility
City
Region
Status
University Hospital Schleswig-Holstein
Kiel
Germany
Recruiting
More MMI (Medical Microinstruments, Inc.) trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.